Sat, Feb 28, 2015, 2:51 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Lpath Inc. Message Board

  • SortNewest  |  Oldest  |  Most Replied Expand all replies
    • harriganrobert@rocketmail.com harriganrobert Nov 30, 2011 2:59 PM Flag

      Even back in 2009 the handwriting was on the wall! Bio R&D is the future ask Pfizer!


      Abstract
      Biotechnol J. 2009 Jul;4(7):1028-41.

      Molecular facets of sphingolipids: mediators of diseases.

      Ozbayraktar FB, Ulgen KO.
      Source

      Department of Chemical Engineering, Bogazici University, Bebek, Istanbul, Turkey.


      Abstract

      Sphingolipids constitute a biologically active lipid class that is significantly important from both structural and regulatory aspects. The manipulation of sphingolipid metabolism is currently being studied as a novel strategy for cancer therapy. The basics of this therapeutic approach lie in the regulation property of sphingolipids on cellular processes, which are important in a cell's fate, such as cell proliferation, apoptosis, cell cycle arrest, senescence, and inflammation. Furthermore, the mutations in the enzymes catalyzing some specific reactions in the sphingolipid metabolism cause mortal lysosomal storage diseases like Fabry, Gaucher, Niemann-Pick, Farber, Krabbe, and Metachromatic Leukodystrophy. Therefore, the alteration of the sphingolipid metabolic pathway determines the choice between life and death. Understanding the sphingolipid metabolism and regulation is significant for the development of new therapeutic approaches for all sphingolipid-related diseases, as well as for cancer. An important feature of the sphingolipid metabolic pathway is the compartmentalization into endoplasmic reticulum, the Golgi apparatus, lysosome and plasma membrane, and this compartmentalization makes the transport of sphingolipids critical for proper functioning. This paper focuses on the structures, metabolic pathways, localization, transport mechanisms, and diseases of sphingolipids in Saccharomyces cerevisiae and humans, and provides the latest comprehensive information on sphingolipid research.
















































      Supplemental Content

    • I also agree. Good article. Large volume today so far, looking forward to afternoon rally.

    • harriganrobert@rocketmail.com harriganrobert Nov 30, 2011 11:56 AM Flag

      Is he another Jonas Salk? If successful ask a blind person!

      Roger A. Sabbadini

      Vice President and Chief Scientific Officer

      Lpath, Inc.

      San Diego , CA

      Sector: HEALTHCARE / Biotechnology

      Officer since January 199764 Years Old

      Dr. Sabbadini founded Lpath Therapeutics, Inc. in 1997 and has served as the Chief Scientific Officer since its inception. Dr. Sabbadini is professor emeritus of Biology at San Diego State University (SDSU), and is the founder of three biotechnology companies incubated out of San Diego State University. Dr. Sabbadini?s lab is focused on developing novel therapeutics for the treatment of sphingolipid-related diseases. Dr. Sabbadini is a Charter Member of the SDSU Molecular Biology Institute and a Charter Member of the SDSU Heart Institute. He holds a Ph.D. from the University of California, Davis.

      Compensation for 2010

      Salary $220,000.00

      Bonus $13,800.00

    • im not sure anyone could buy them for less than 1-1.5 bil .....and if trials are good....forgitaboutit for that price...jmo

    • Agreed! This really puts it out there as simply as possible. No wonder the volume has been pouring in to this stock.

 
LPTN
2.93-0.06(-2.01%)Feb 27 3:57 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.